Variant Synonymizer: Platform to identify mutations defined in different ways is available now!

VarSy

Over 2,000 gene–disease validation summaries are now available—no login required!

Browse Summaries

SOX3 – Septooptic Dysplasia

SOX3 is implicated in X-linked Septooptic dysplasia with limited clinical evidence. Four probands were reported: two male siblings with a seven-alanine expansion and one unrelated individual with a nonfunctional p.Arg5Gln variant, plus a female with an 18-bp deletion in the polyalanine tract (c.726_743del (p.Ala243_Ala248del)); segregation in the sibship supports X-linked recessive inheritance with one additional affected relative ([PMID:21289259]).

Functional assays demonstrate that the del6PA allele exhibits a twofold increase in transcriptional activation and retains repression of β-catenin–mediated transcription, whereas expansions impair β-catenin repression, suggesting a dosage-sensitive gain-of-function mechanism ([PMID:21289259]). However, the small number of cases and lack of independent replication limit the current diagnostic utility. Key take-home: SOX3 polyalanine tract variants may contribute to septooptic dysplasia via altered transcriptional activity, but further studies are required for clinical validation.

References

  • The Journal of clinical endocrinology and metabolism • 2011 • Increased transactivation associated with SOX3 polyalanine tract deletion in a patient with hypopituitarism. PMID:21289259

Evidence Based Scoring (AI generated)

Gene–Disease Association

Limited

4 probands across one study, single segregating family, concordant functional data ([PMID:21289259])

Genetic Evidence

Limited

4 probands with X-linked polyalanine tract deletion/expansion; segregation in one sibship ([PMID:21289259])

Functional Evidence

Moderate

In vitro assays show increased transactivation for del6PA and impaired β-catenin repression for expansions ([PMID:21289259])